Report a pregnancy exposure

The United States (U.S.) Pregnancy Surveillance Program has been established to monitor pregnancy outcomes in individuals exposed to VERQUVO® (vericiguat) during pregnancy.

VERQUVO may cause birth defects if taken during pregnancy. Females must not be pregnant when they start taking VERQUVO. Females of reproductive potential must use effective forms of birth control during treatment and for 1 month after you stop treatment with VERQUVO.

Please select from the options below for additional information regarding the U.S. Pregnancy Surveillance Program:

To report an adverse event or product quality complaint in the U.S., please contact the company at 1-800-672-6372. If you are outside the U.S., please contact your local MSD office.